What is ARS Pharmaceuticals, Inc.'s SG&A?

ARS Pharmaceuticals, Inc. (SPRY) reported SG&A of $72.2M in Q1 2026.

How has ARS Pharmaceuticals, Inc.'s SG&A changed year-over-year?

ARS Pharmaceuticals, Inc.'s SG&A increased by 75.7% year-over-year, from $41.1M to $72.2M.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

ARS Pharmaceuticals, Inc. SPRY SG&A

SG&A at other companies

Amneal Pharmaceuticals, Inc.AMRX

$138.86M+17.4%

ViatrisVTRS

$928.8M-2.0%

Catalyst PharmaceuticalCPRX

$49.32M+5.1%

Other financials

Income statement

See full

Revenue$22.7M+184%

Operating income-$60.1M-61.8%

Net income-$60.6M-78.6%

EPS (diluted)-$0.61-74.3%

Balance sheet

See full

Cash & equivalents$24.3M-39.0%

Total debt$96.5M+132,122%

Total equity$61.3M-73.2%

Total assets$287.6M-12.1%

Cash flow

See full

Operating cash flow-$44.9M-10.3%

CapEx--100%

Free cash flow-$44.9M-10.1%

Valuation

See full

Market cap$796.41M-48.7%

Enterprise value$868.61M-42.6%

P/S8.1×-7.9×

Profitability

See full

Operating margin-204.5%—

Net margin-200%-219pp

FCF margin-177.1%-206pp

Returns & leverage

See full

Return on equity-136.4%-144pp

Debt / equity1.6×+1.6×

Current ratio4.9×-6.1×

Where this comes from

Reported directly by ARS Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about ARS Pharmaceuticals, Inc.'s sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ARS Pharmaceuticals, Inc.'s SG&A?: ARS Pharmaceuticals, Inc. (SPRY) reported SG&A of $72.2M in Q1 2026.
How has ARS Pharmaceuticals, Inc.'s SG&A changed year-over-year?: ARS Pharmaceuticals, Inc.'s SG&A increased by 75.7% year-over-year, from $41.1M to $72.2M.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.